Evidence map›Paper›PMID 41256624›Full record

ArticlebioRxiv : the preprint server for biology2025

Neuroprotective Parkinson's Disease Therapeutic: Transition Metal Dichalcogenide Nanoflower Treatments Alleviate Pathological Cell Stress.

Charles L Mitchell, Mikhail Matveyenka, Harris C Brown, Jessica Aldape, Payton Moore, Kha-Tran Nguyen, John C Walker, Bryce Pearson, Joshua Skrehot, Dmitry Kurouski

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charles L MitchellInterdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, Texas, USA.ORCID 0009-0005-0992-1572
Mikhail MatveyenkaDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Harris C BrownDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Jessica AldapeDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Payton MooreDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Kha-Tran NguyenDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
John C WalkerDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Bryce PearsonDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Joshua SkrehotDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Dmitry KurouskiInterdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, Texas, USA.

Funding

Biophysical determination of the underlying cause of α-Syn oligomer toxicityR35GM142869 · NIGMS · TEXAS A&M AGRILIFE RESEARCH · PI KUROUSKI, DMITRY · 2021 to 2025
$1.6M
NIGMS NIH HHS R35 GM142869
6 · The paper itself

Abstract

Parkinson's disease (PD) is triggered by irreversible degeneration of dopaminergic neurons in the midbrain, hypothalamus, and thalamus. Although the underlying molecular etiology of these pathological processes remains unclear, progressive aggregation of alpha-synuclein (α-syn) and mitochondrial dysfunction are two expected mechanisms implicated in neuronal degeneration. Accumulating evidence indicates that transition metal dichalcogenide (TMD) nanoflowers (NFs), a novel class of nanomaterials, can restore mitochondrial health by the activation of mitochondrial biogenesis. However, therapeutic potential of TMD NFs in PD remains unclear. The current study investigates the neuroprotective properties of molybdenum disulfide (MoS

Identifiers

PMID41256624
PMCPMC12621851

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.